Prudential Financial Inc. Reduces Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Prudential Financial Inc. trimmed its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 57.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,121 shares of the life sciences company's stock after selling 120,100 shares during the quarter. Prudential Financial Inc. owned about 0.11% of Integra LifeSciences worth $1,999,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC purchased a new position in Integra LifeSciences during the 4th quarter worth $180,000. Romano Brothers AND Company acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth $204,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $204,000. Finally, Centiva Capital LP acquired a new position in shares of Integra LifeSciences during the third quarter worth about $192,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Shares of IART stock traded up $1.12 during midday trading on Wednesday, reaching $19.19. 1,223,982 shares of the company traded hands, compared to its average volume of 1,049,461. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $34.41. The firm has a market cap of $1.48 billion, a PE ratio of -213.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The firm's 50 day simple moving average is $22.63 and its two-hundred day simple moving average is $22.31. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period in the previous year, the business earned $0.89 earnings per share. Integra LifeSciences's quarterly revenue was up 11.5% compared to the same quarter last year. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.